News Celgene hopes device + drug can tackle aggressive brain tumo... Novocure's Optune will be tested alongside investigational Celgene drug marizomib.
News Head patch device Optune improves brain cancer survival Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
News Electrical patch device shows promise against ovarian cancer Novocure's Optune device shown to be safe and tolerable in recurrent ovarian cancer.
News Aldeyra’s reproxalap for dry eye disease accepted by FDA Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New D
News Welcome to the new pharmaphorum Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved
